☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Novartis
Novartis Reports Longer-Term Results from P-III (NATALEE) Trial of Kisqali (Ribociclib) to Treat Early Breast Cancer
December 11, 2024
Novartis’ Kisqali (Ribociclib) Secures EC’s Approval as an Adjuvant Treatment of HR+/HER2- Early Breast Cancer
November 27, 2024
Novartis Reports the Acquisition of Kate Therapeutics for ~$1.1B
November 22, 2024
The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase
October 30, 2024
Monte Rosa Therapeutics and Novartis Collaborate to Advance VAV1-directed Molecular Glue Degraders (MGD)
October 29, 2024
Novartis Reports Data from P-III (APPEAR-C3G) Study of Fabhalta (Iptacopan) in C3 Glomerulopathy (C3G)
October 28, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.